Clinical Trial Update: Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial evaluating switching to VM-1500A-LAI + 2 NRTIs from first-line ART for HIV-1 infection (Phase 2/3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• 2 NRTIs
• VM-1500A-LAI

Snippet

Sponsor: Viriom | Conditions: HIV-1-infection | Phase 2, Phase 3 | Status: UNKNOWN